Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect by Yamada, Kohji et al.
BioMed  Central
C
TIONAL INTERNA
CANCER CELL
Page 1 of 9
(page number not for citation purposes)
Cancer Cell International
Open Access Primary research
Localization of CD26/DPPIV in nucleus and its nuclear translocation 
enhanced by anti-CD26 monoclonal antibody with anti-tumor effect
Kohji Yamada1, Mutsumi Hayashi1, Wenlin Du1, Kei Ohnuma2, 
Michiie Sakamoto1, Chikao Morimoto2 and Taketo Yamada*1
Address: 1Department of Pathology, Keio University School of Medicine, Tokyo, Japan and 2Division of Clinical Immunology, Advanced Clinical 
Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
Email: Kohji Yamada - kohji@z8.keio.jp; Mutsumi Hayashi - mutsumi@mtb.biglobe.ne.jp; Wenlin Du - duwenlin@sc.itc.keio.ac.jp; 
Kei Ohnuma - kays@ims.u-tokyo.ac.jp; Michiie Sakamoto - msakamot@sc.itc.keio.ac.jp; Chikao Morimoto - morimoto@ims.u-tokyo.ac.jp; 
Taketo Yamada* - taketo@sc.itc.keio.ac.jp
* Corresponding author    
Abstract
Background: CD26 is a type II, cell surface glycoprotein known as dipeptidyl peptidase (DPP) IV.
Previous studies have revealed CD26 expression in T cell leukemia/lymphoma and malignant
mesothelioma, and an inhibitory effect of anti-CD26 monoclonal antibody (mAb) against the
growth of CD26+ cancer cells in vitro and in vivo. The function of CD26 in tumor development is
unknown and the machinery with which the CD26 mAb induces its anti-tumor effect remains
uncharacterized.
Results:  The localization of CD26 in the nucleus of T cell leukemia/lymphoma cells and
mesothelioma cells was shown by biochemical and immuno-electron microscopic analysis. The
DPPIV enzyme activity was revealed in the nuclear fraction of T cell leukemia/lymphoma cells.
These expressions of intra-nuclear CD26 were augmented by treatment with the CD26 mAb, 1F7,
with anti-tumor effect against the CD26+ T cell leukemia/lymphoma cells. In contrast, the CD26
mAb, 5F8, without anti-tumor effect, did not augment CD26 expressions in the nucleus. Biotin-
labeled, cell surface CD26 translocated into the nucleus constantly, and this translocation was
enhanced with 1F7 treatment but not with 5F8.
Conclusion:  These results indicate that the intra-nuclear CD26 which moves from plasma
membrane may play certain roles in cell growth of human cancer cells.
Background
CD26 is a 110 kDa transmembrane glycoprotein
expressed in many different cells and tissues, including T
lymphocytes, melanocytes, epithelia of the renal tubule or
colonic mucosa, and endothelial cells. It consists of three
domains, a cytoplasmic short tail domain with only 6
amine residues, a transmembrane domain, and an extra-
cellular domain. This extracellular domain possesses the
activity of a membrane-associated ectopeptidase known
as dipeptidyl peptidase (DPP) IV that preferentially
cleaves N-terminal dipeptides from polypeptides with L-
proline or L-alanine in the penultimate position. It binds
proteins such as adenosine deaminase (ADA), CD45, and
a part of the extracellular matrix (ECM) [1]. On T lym-
phocytes CD26 regulates expression of ADA on the cell
surface, with the CD26/ADA complex playing a key role in
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the catalytic removal of local adenosine to regulate
immune system function [2]. CD26 also functions as a co-
stimulatory factor in the CD3 and CD2 pathways of acti-
vation, as well as acting as an alternate pathway for T lym-
phocyte activation when cross-linked with solid-phase,
immobilized specific monoclonal antibodies (mAbs) [3].
CD26 is expressed in many kinds of human malignancy,
including mesothelioma, renal cell carcinoma, and T cell
leukemia/lymphoma. CD26 expression is observed in
mesothelioma cells, but not in non-neoplastic mesothe-
lial cells [4]. The murine CD26 mAbs, 1F7 and 14D10,
which recognize the cell membrane-proximal glyco-
sylated region starting with a 20-amino acid flexible stalk
region of human CD26, are reported to have anti-tumor
effects against T cell leukemia/lymphoma, mesothelioma
and renal carcinoma cells, both in vitro and in vivo [4-6].
These mAbs induce the arrest of the G1/S cell cycle, con-
comitant with blocking the adhesion of cancer cells to the
ECM in mesothelioma cells and renal carcinoma cells
[4,5]. The CD26 mAb, 1F7, inhibits the cell growth of T
lymphocytes and modulates the expression of cell surface
CD26 in T-cell clones [3,6-8]. The 1F7-induced modula-
tion of CD26 is found to be a dynamic process following
the capping and internalization of the antigen-antibody
complex. 1F7 induces p21 expression via de novo protein
synthesis, followed by G1/S cell cycle arrest. It is, however,
unknown how CD26, stimulated with 1F7, induces p21
expression.
Previous reports showed the localization of CD26 on the
plasma membrane, the endoplasmic reticulum (ER), and
the lysosome, by ultrastructural analysis [9,10]. We herein
show with biochemical and morphological analysis,
localization of CD26, not only on the cell surface and in
the lysosome, but also in the nucleus of human cancer
cells. We also assessed whether the anti-tumor activity of
the CD26 mAb, 1F7, against T-cell leukemia/lymphoma
cells, correlated with the translocation of CD26 into
nucleus of human tumor cells.
Results and discussion
The presence of CD26/DPPIV in the nucleus
We assessed the subcellular localization of CD26 by bio-
chemical analysis. Karpas 299 cells and JMN cells, with
endogenous CD26 expression, were fractionated into
membrane, cytoplasmic, or nuclear fractions. By immu-
noblotting, CD26 was detected as a 110 kDa band in the
nuclear fraction, as well as in the membrane and cytoplas-
mic fractions (Fig. 1A and 1B). CD26 expression was also
observed in the nuclear, membrane and cytoplasmic frac-
tions of J/CD26 cells, but not in any fractions of J/Wt cells
(known to be CD26-negative cells at both the protein and
mRNA level) [11] (Fig. 1C). Mesothelioma cell line JMN
relatively exhibits higher CD26 level in the nuclear frac-
tion than that in two T cell lines, Karpas 299 and J/CD26
cells. The difference may be due to difference in cell line-
ages between mesothelioma cell and T lymphocyte. To
confirm the 110 kDa band observed in immunoblotting
was indeed CD26, CD26 was immunoprecipitated from
each fraction of the JMN cells with the murine CD26
mAb, 1F7, and detected by immunoblotting with a CD26
pAb. The 110 kDa band was confirmed as the CD26 pro-
tein. However, no NLS sequence of CD26, which is
defined as cluster of a series of basic amino acids, is found
by PSORT II program that predicts subcellular localization
http://www.psort.org. CD26 may be required to associate
with other partner molecules to move to the nucleus.
Immunoelectron microscopic analysis of Karpas 299 and
JMN cells showed immunogold labeled-CD26 on the cell
surface side of the plasma membrane and in the lyso-
some, as previously reported [9,10] (Fig. 2A). In addition,
immunogold particles were diffusely observed in the
nucleus of the Karpas 299 cells (Fig. 2A), while in the JMN
cells, the immunogold particles were clustered in areas of
high electron density (such as the chromatin structure) in
the nucleus (Fig. 2B).
The CD26 in nucleus was assessed for DPPIV enzyme
activity. As a result, specific enzyme activity was detected
in the nuclear fraction (and the cytosolic fraction) of both
the J/CD26 cells and the Karpas 299 cells (Fig. 2C and
2D). DPPIV activity in the nuclear fraction was also
observed following fractionation by an alternative
method (Qproteome cell compartment kit, Qiagen) using
J/CD26 cells and the JMN mesothelioma cells (data not
shown). This DPPIV activity in the nuclear and cytosolic
fraction was inhibited by treatment with diprotin A, an
inhibitor of the DPPIV enzyme (Fig. 2C and 2D). These
data suggest that CD26/DPPIV functions as a catalytic
enzyme against, as yet, unidentified molecules in the
nucleus.
Effect of the CD26 mAb, 1F7, on the nuclear localization 
of CD26
We examined whether a change in CD26 localization into
the nucleus could be initiated by treatment with the CD26
mAb, 1F7, since 1F7 treatment was shown to induce inter-
nalization of CD26 from the plasma membrane into the
cytoplasm of CD26+ T-cells [7]. CD26 levels in the
nuclear fraction of J/CD26 cells were found to be at a peak
within one hour of treatment with 1F7, but not 5F8 or
IgG1 (Fig. 3A). Accordingly, CD26 levels in the membrane
fraction were decreased within one hour of 1F7 treatment
(Fig. 3B). The augmentation of CD26 in the nuclear frac-
tion following 1F7 treatment may be an extreme early
event because the increased localization of CD26 in
nuclear fraction was also observed at the zero hour time
point. The increased amount of CD26 at zero time pointCancer Cell International 2009, 9:17 http://www.cancerci.com/content/9/1/17
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seems to depend on some reactions during extra con-
sumed time indispensable for experimental procedure.
On the other hand, the CD26 mAb, 5F8, which recognizes
a distinct epitope to 1F7, did not influence the nuclear
localization of CD26. 1F7 reportedly inhibits the cellular
proliferation of T-cells in vitro, while no such inhibitory
effect has been observed with 5F8 [5,8]. Thus, the translo-
cation of CD26 into the nucleus, following 1F7 treatment,
may result in the inhibition of cell growth in an epitope-
specific manner.
Translocation of CD26 into the nucleus following 1F7 
treatment
The observed enhanced localization of CD26 in the
nucleus, and the concomitant decrease of CD26 in the
membrane fraction, following 1F7 treatment, suggests
that CD26 on the cell surface moves into the nucleus as a
result of stimulation with 1F7. Thus, we biotin-labeled J/
CD26 cell surface proteins and these were chased follow-
ing 1F7 treatment. Biotin-labeled CD26 levels increased
dramatically in the nuclear fraction within one hour fol-
Nuclear localization of CD26 Figure 1
Nuclear localization of CD26. (A-C) Equal amounts of membrane, cytoplasm and nuclear extracts from (A) Karpas 299 
cells, (B) JMN cells, and (C) J/Wt cells and J/CD26 cells were immunoblotted with CD26 pAb.
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Nuclear localization of CD26/DPPIV Figure 2
Nuclear localization of CD26/DPPIV. (A and B) Immuno-electron microscopy in (A) Karpas 299 cells (scale bar: 200 nm) 
and (B) JMN cells (scale bar: 1 μm). (C and D) The activity of DPPIV. J/Wt, J/CD26 or Karpas 299 cells were measured in (C) 
nuclear and (D) cytosolic fractions. Data are the means ± s.d. for each representative experiment, which was performed in 
triplicate.
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Increase of CD26 in nucleus following treatment with CD26 mAb, 1F7 Figure 3
Increase of CD26 in nucleus following treatment with CD26 mAb, 1F7. J/CD26 cells were incubated with media con-
taining the CD26 mAbs, 1F7 or 5F8, or control mouse IgG1. After incubation for 0, 1, or 6 hours, the cells were separated into 
(A) nuclear and (B) membrane fractions and CD26 proteins were immunoblotted. Coomassie brilliant blue (C.B.B.) staining 
was shown. Representative CD26 expression was shown. Similar results were obtained in three independent experiments.
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Translocation of CD26 into nucleus from cell surface Figure 4
Translocation of CD26 into nucleus from cell surface. (A and B) Cell surface biotin-labeling of (A) J/CD26 cells and (B) 
Karpas 299 cells. Cells were treated with/without sulfo-NHS-biotin, and incubated with 1F7 or IgG1 for (A) 0, 1 and 3 hours, or 
for (B) 1 hour. The cells were separated into nuclear and membrane fractions, immunoprecipitated with CD26 mAb, and 
immunoblotted. (C) J/Wt cells and J/CD26 cells were treated with biotin-labeled antibodies (1F7 or control IgG1) and sepa-
rated into nuclear and membrane fractions. The biotinylated antibody-bound proteins were purified on beads immobilized to 
NeutrAvidin and separated by SDS-PAGE. Representative CD26 expression was shown. Similar results were obtained in three 
independent experiments.
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lowing 1F7 treatment (Fig. 4A). In contrast with the
nuclear fraction, biotin-labeled CD26 decreased in the
membrane fraction within one hour following 1F7 treat-
ment (Fig. 4A). Thus, cell surface CD26 appears to trans-
locate into the nucleus following 1F7 treatment. In
addition, it appeared that this translocation of CD26 into
the nucleus from the cell surface was constant as biotin-
CD26 was always observed in the nuclear fraction, before
and after treatment with IgG1 (Fig. 4A). Karpas 299 cells
express CD26 endogenously, and our previous report has
shown that cell cycle arrest in Karpas 299 cells related to
p21 expression is induced following 1F7 treatment [6].
Therefore we investigated the effect of 1F7 on transloca-
tion of CD26 into nucleus of Karpas 299 cells. As a result,
like J/CD26 cells, biotin-CD26 increased in the nuclear
fraction of Karpas 299 cells following stimulation with
1F7, compared with IgG1 (Fig. 4A and 4B). These results
indicate that cell surface CD26 is constantly translocated
into the nucleus, and 1F7 treatment enhances this translo-
cation. On the other hand, in JMN cells, these effects of
1F7 were slight. We think this discrepancy may be
explained by the difference of cell lineage and nuclear
CD26 amount before the 1F7 treatment (Fig. 1A and 1B).
To confirm the augmentation of CD26 translocation into
the nucleus by 1F7, we assessed whether biotin-labeled
1F7 could enhance this CD26 translocation in J/Wt and J/
CD26 cells. CD26 bound to biotin-1F7 was detected in
the nuclear fraction and the membrane fraction of J/CD26
cells, in contrast with biotin-IgG1 (Fig. 4C, top panel). The
biotin-1F7 enhanced CD26 translocation into the nuclear
fraction from the membrane fraction (Fig. 4C, middle
panel), confirming that the biotinylation of 1F7 did not
influence the induction of CD26 translocation. These data
show that the specific binding of 1F7 to a particular
epitope on CD26 may induce the translocation of cell sur-
face CD26 into the nucleus. However, the mechanism of
this translocation of CD26 into nucleus, and the augmen-
tation by 1F7 treatment, remains unknown.
Previous reports show that membrane-associated pro-
teins, such as the epidermal growth factor receptor (EGFR)
family [12-14], fibroblast growth factor receptor (FGFR)-
1 [15,16], heparin-binding EGF-like growth factor (HB-
EGF) [17], and CD40 [18], are shuttled from the plasma
membrane into the nucleus. The translocation of these
molecules into the nucleus can also be elevated by stimu-
lation with, for example, specific ligands for the receptor,
and the ectodomain shedding of proHB-HGF at the extra-
cellular region on the plasma membrane. These mem-
brane-associated molecules transmit specific signals from
the cell surface to the nucleus after stimulation, and travel
directly to the nucleus via internalization. The receptors
that are transported into the nucleus have a common
function as transcription regulators. There is no evidence
that CD26 functions as transcriptional regulator, but a
study which silenced CD26 using small interfering RNA
showed an increase in basic FGF in prostate cancer cells in
vitro [19]. Altered gene expression, mediated by CD26,
may indicate a novel function of CD26 in the nucleus.
DPPIV activity in the nucleus may be also implicated in
the intra-nucleus dynamics by regulating the activation of
unknown substrates of DPPIV in the nucleus.
These results permit us to speculate that nuclear events,
such as transcription or cell growth, may be regulated by
nuclear CD26.
Conclusion
We observed that CD26 was constantly present in the
nucleus of CD26+ cancer cells and the nuclear transloca-
tion of CD26 from cell surface was augmented by the
treatment with anti-CD26 monoclonal antibody with
anti-tumor effect in epitope-specific manner. These results
suggest that intra-nuclear CD26/DPPIV may play an
important role in the proliferation or survival of cancer
cells. The CD26 therefore represents a potential new ther-
apeutic target in human cancer could be considered.
Methods
Cell culture
Karpas 299 cells (derived from an anaplastic, large T-cell
lymphoma) [6], JMN cells (derived from a mesotheli-
oma) [4], Jurkat cells (J/Wt), and Jurkat cells containing a
CD26 expression vector (J/CD26) [8], were cultured at
37°C in RPMI 1640 medium supplemented with 10%
fetal bovine serum, 100 units/mL penicillin, and 100 μg/
mL streptomycin.
Subcellular fractionation and immunoblotting
Cells were incubated in medium with/without the CD26
mAbs, 1F7 or 5F8 (2 μg/mL), or control mouse IgG1
(Dako Cytomation, Denmark). After appropriate incuba-
tion, cells were harvested and washed with PBS. Mem-
brane, cytoplasm and nuclear fractions were extracted
using the Qproteome cell compartment kit, and according
to the manufacturer's instructions (Qiagen, Hilden, Ger-
many). The membrane fraction contains endosomes and
membrane-compartmented organelles, such as mito-
chondria and the ER, as well as cell surface plasma mem-
brane. Protein concentrations of each fraction were
determined using the BCA protein assay kit (Pierce Bio-
technology, Rockford, IL, USA). Equal amounts of protein
were subjected to 10% SDS-PAGE and transferred to a pol-
yvinylidene fluoride (PVDF) membrane. The membranes
were probed with the following antibodies: anti-CD26
polyclonal antibody (pAb) (R&D systems, Mineapolis,
MN, USA), anti-Na+/K+ATPase mAb (Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA, USA) as a plasma membrane
marker, anti-culreticulin mAb (BD Pharmingen, SanCancer Cell International 2009, 9:17 http://www.cancerci.com/content/9/1/17
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Diego, CA) as an ER marker, anti-calpain-1/2 mAb (Calbi-
ochem, La Jolla, CA) as a cytoplasmic marker, anti-lamin
A/C mAb (Santa Cruz) as a nuclear marker, and anti-
nucleostemin Ab (Qiagen) as a nuclear marker. Signals
were revealed by enhanced chemiluminescence (ECL).
Relative CD26 amounts for representative experiment
were quantitatively analyzed with the Image Quant 350
software (GE healthcare, UK) and represented as percent-
age of CD26 expression in each fraction.
Immunoelectron microscopic analysis
Karpas 299 cells and JMN cells were fixed on ice overnight
in 0.1 M cacodylate buffer (0.1% glutaraldehyde and 4%
paraformaldehyde, pH 7.4). The cells were dehydrated by
two, 5-min incubations in 50, 70, 95, and 100% dimeth-
ylformamide in water. Cell pellets were incubated in
dimethylformamide/lowicryl (1:1) for 30 min at room
temperature. Sections (8 nm) were cut and mounted on
copper mesh with 150 grids, incubated with a CD26 pAb
(Santa Cruz) overnight, washed four times with PBS, and
labeled for 60 min with a secondary, 15-nm gold-immu-
nolabeled, anti-rabbit antibody. Sections were washed
with 2% uranyl acetate, followed by 4% lead citrate and
visualized with an electron microscope.
DPPIV activity assay
Nuclear and cytosol fractions were prepared as described
[15,20], with some modifications. Briefly, cells ware
washed with PBS and resuspended in 400 μL of ice-cold
buffer containing 10 mM HEPES (pH 7.4), 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, and protease inhibitor
(Roche, Mannheim, Germany). The cells were allowed to
swell on ice for 15 min, at which time 25 μL of 10% NP-
40 was added, and the cells vortexed vigorously for 10 s.
Nuclei were pelleted by centrifugation, washed twice with
ice-cold buffer containing NP-40, and resuspended in 150
μL nuclear extract buffer containing 20 mM HEPES (pH
7.4), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA and protease
inhibitor (Roche). Equal amounts (5 μg) of fractionated
proteins were seeded onto 96-well plates and incubated in
the presence or absence of diprotin A (an inhibitor of the
DPPIV enzyme) (200 μM; Sigma, St. Louis, MI, USA), and
the DPPIV substrate Gly-Pro-aminoluciferin (DPPIV-Glo
protease assay; Promega, Madison, WI), and gently mixed.
Plates were incubated for 30 min in the buffer system
optimized for DPPIV and luciferase activity. Luciferase
activity was assessed with a luminometer.
Cell surface biotinylation and Immunoprecipitation
Cells were washed twice with PBS containing 1 mM CaCl2
and 0.5 mM MgCl2 (PBS-CM), at 4°C, and incubated for
12 min at 4°C in 1.0 mg/mL N-hydroxysulfosuccinimide
(sulfo-NHS)-Biotin (Pierce) dissolved in PBS-CM. To
quench unreacted biotin, cells were washed three times
with PBS-CM plus 50 mM glycine and washed twice with
PBS [21,22]. After incubation with the indicated antibod-
ies, immunoprecipitation was performed using the CD26
mAb, 1F7 (2 μg), with equal amounts of protein from
each fraction, overnight at 4°C. The antibody was bound
directly to Protein A Sepharose beads for 1 h at 4°C. The
beads were washed four times with NET-2 buffer [23] and
the bound proteins eluted by directly adding SDS loading
buffer to the beads.
Biotinylation of antibodies
1F7 and control mouse IgG1 were biotinylated using a
biotin labeling kit (Roche). Cells were incubated with cul-
ture medium containing the biotin-labeled antibodies for
1 h at 37°C. After washing with PBS, the cells were subcel-
lular fractionated. Equal amounts of protein were precip-
itated with immobilized NeutrAvidin (Pierce) overnight
at 4°C. The beads were washed four times with NET-2
buffer, and precipitated, biotinylated proteins were eluted
by adding SDS sampling buffer.
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